# DEFB125

## Overview
DEFB125 is a gene that encodes the protein defensin beta 125, a member of the defensin family known for its role in the innate immune system. Defensin beta 125 is a small, cysteine-rich, cationic protein that functions primarily as an antimicrobial agent, disrupting the membranes of pathogens such as bacteria, fungi, and viruses. This disruption is achieved through the protein's ability to integrate into and destabilize microbial lipid bilayers, leading to cell lysis. The gene is expressed in various human tissues, contributing to localized immune responses and serving as a critical component of the body's first line of defense against infections. DEFB125's involvement in immune regulation and its potential implications in diseases such as Alzheimer's and certain cancers highlight its clinical significance (Aibar2016Identification; Castiglione2013Karyotype-Phenotype; Wozniak2021Molecular).

## Function
DEFB125, or defensin beta 125, is a member of the defensin family, which plays a critical role in the innate immune response. These proteins are characterized by their small size, cysteine-rich structure, and cationic nature, which enable them to exert antimicrobial activity. DEFB125 is involved in the disruption of microbial membranes, a process that is essential for protecting the host against a wide range of pathogens, including bacteria, fungi, and viruses. This disruption is achieved through the protein's ability to integrate into and destabilize the lipid bilayers of microbial membranes, leading to cell lysis and death.

In healthy human cells, DEFB125 is expressed in various tissues, contributing to the first line of defense against infections. By maintaining the integrity of cellular and organismal homeostasis, DEFB125 helps to prevent the establishment and spread of infections. Its activity is crucial for the immediate immune response, providing a rapid and effective means of controlling microbial populations before the adaptive immune system is activated. The presence of DEFB125 in different tissues suggests its involvement in localized immune responses, ensuring that potential pathogens are neutralized at the site of entry or infection. This localized action is vital for maintaining overall health and preventing systemic infections.

## Clinical Significance
DEFB125 (defensin beta 125) has been implicated in several clinical contexts, particularly in relation to Alzheimer's Disease (AD). In the progression of AD, DEFB125 is among the nine up-regulated genes identified in a specific expression pattern, suggesting its association with the disease. This upregulation indicates a potential role in the altered immune response observed in Alzheimer's patients (Aibar2016Identification).

In the context of chromosomal abnormalities, DEFB125 is located on the short arm of chromosome 6. Deletions involving DEFB125 and other β-defensin family members have been associated with increased susceptibility to infections, highlighting its role in immune system function (Castiglione2013Karyotype-Phenotype).

Additionally, a study on leiomyosarcoma patients identified a loss of DEFB125 on chromosome 20p13, which was associated with inferior overall survival in a specific treatment subcohort. This suggests that alterations in DEFB125 may influence cancer prognosis, although the exact mechanisms remain unclear (Wozniak2021Molecular).

These findings underscore the potential clinical significance of DEFB125 in various diseases, particularly those involving immune dysregulation and cancer. Further research is needed to fully elucidate its role and therapeutic potential.

## Interactions



## References


[1. (Aibar2016Identification) Sara Aibar, Maria Abaigar, Francisco Jose Campos-Laborie, Jose Manuel Sánchez-Santos, Jesus M. Hernandez-Rivas, and Javier De Las Rivas. Identification of expression patterns in the progression of disease stages by integration of transcriptomic data. BMC Bioinformatics, November 2016. URL: http://dx.doi.org/10.1186/s12859-016-1290-4, doi:10.1186/s12859-016-1290-4. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12859-016-1290-4)

[2. (Castiglione2013Karyotype-Phenotype) A. Castiglione, V. Guaran, L. Astolfi, E. Orioli, G. Zeri, D. Gemmati, R. Bovo, A. Montaldi, A. Alghisi, and A. Martini. Karyotype-phenotype correlation in partial trisomies of the short arm of chromosome 6: a family case report and review of the literature. Cytogenetic and Genome Research, 141(4):243–259, 2013. URL: http://dx.doi.org/10.1159/000353846, doi:10.1159/000353846. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000353846)

[3. (Wozniak2021Molecular) Agnieszka Wozniak, Bram Boeckx, Elodie Modave, Amy Weaver, Diether Lambrechts, Bruce A. Littlefield, and Patrick Schöffski. Molecular biomarkers of response to eribulin in patients with leiomyosarcoma. Clinical Cancer Research, 27(11):3106–3115, April 2021. URL: http://dx.doi.org/10.1158/1078-0432.CCR-20-4315, doi:10.1158/1078-0432.ccr-20-4315. This article has 11 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.CCR-20-4315)